Shukra Pharmaceuticals, a company in the Pharmaceuticals industry, reported revenue of ₹44 crore and net profit of ₹16 crore for the September 2026 quarter.
Shukra Pharmaceuticals (NSE: SHUKRAPHAR) closed at ₹84.20 on 20 Nov 2026. Its market capitalisation is ₹3,726 crore and it trades at 84.1 times earnings.
Incorporated in 1993, Shukra Pharmaceuticals Ltd manufactures and markets pharmaceutical products, and does laboratory testing
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.